Background The efficacy of direct oral anti-coagulants (DOACs) for the treatment of venous
thromboembolism (VTE) in Japanese patients with advanced cancer is largely unknown …

Background: The efficacy and bleeding complications of direct oral anticoagulant (DOAC)
therapy for cancer-associated venous thromboembolism (VTE) in routine clinical practice …

Background/Aim: Although direct oral anti-coagulants (DOACs) are as safe and effective as
conventional anticoagulants for treating venous thromboembolism (VTE), we have …

Purpose The standard of care for the treatment of cancer-related venous thromboembolism
(VTE) is a low molecular weight heparin (LMWH) formulation. The recent development of …

Low molecular weight heparins (LMWHs) are considered the standard of care for the
treatment of venous thromboembolism (VTE) associated with cancer. We conducted a meta …

Background There is a paucity of data on real-world management strategies and clinical
outcomes of cancer-associated venous thromboembolism (VTE) in the direct oral …

Cancer-associated thrombosis (CAT) poses a significant disease burden and the incidence
in Asian populations is increasing. Anticoagulation is the cornerstone of treatment, but can …

Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …

Introduction Real-world evidence on the effects of direct oral anticoagulants (DOACs) in
patients with cancer associated venous thromboembolism (VTE) is limited. Thus, our …

Background: The efficacy and safety of newer oral anticoagulants (NOAs) compared to
vitamin K antagonist (VKA) in preventing the recurrence of venous thromboembolism (VTE) …